Polymorphisms in the promoter region of the basic fibroblast growth factor gene and proliferative diabetic retinopathy in Caucasians with type 2 diabetes

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Basic fibroblast growth factor (bFGF) expression is implicated in proliferative diabetic retinopathy (PDR). The aim of this study was to investigate the association of genetic polymorphisms (−553T/A, −834T/A and −921C/G) in the promoter region of the bFGF gene with PDR in patients with type 2 diabetes. The second aim was to determine whether serum levels of bFGF are affected by genetic factors.

Methods

In this cross-sectional case–control study 313 unrelated Caucasians (Slovene population) with type 2 diabetes mellitus were enrolled: 206 patients with PDR and the control group of 107 subjects with type 2 diabetes of duration of more than 10 years who had no clinical signs of diabetic retinopathy. We analysed serum bFGF levels in 78 subjects with type 2 diabetes and 25 subjects without diabetes.

Results

The AT genotype of the −553T/A polymorphism was present in 31 (15.0%) PDR patients and in seven (6.5%) controls (P= 0.03, odds ratio = 2.0, 95% confidence interval = 1.0–3.9). The AT genotype of the −834T/A polymorphism was present in 12 (5.8%) PDR patients and in 15 (14.0%) controls (P= 0.01, odds ratio = 0.4, 95% confidence interval = 0.2–0.8). Significantly higher bFGF serum levels were demonstrated in diabetics with the AT genotype of the −553 polymorphism compared with diabetics with the TT genotype, whereas the −834 and −921 polymorphisms failed to affect serum bFGF levels.

Conclusions

We may conclude that the AT genotype of the 553 T/A polymorphism was associated with PDR in Caucasians with type 2 diabetes, therefore it might be used as a genetic marker of PDR in Caucasians, whereas carriage of the AT genotype of the −834 T/A polymorphism might decrease PDR risk.

Related Topics

    loading  Loading Related Articles